FBXL6 and acute myeloid leukemia: Taken together, we here nominate the ubiquitin ligase FBXL6 as a potential novel vulnerability in AML, thus providing further evidence for the important role of PTMs and specifically the ubiquitin system as a potential therapeutic target in AML.